FEV1/FVC ratio

Last updated
Lungvolumes Updated.png
TLCTotal lung capacity: the volume in the lungs at maximal inflation, the sum of VC and RV.
TVTidal volume: that volume of air moved into or out of the lungs in 1 breath (TV indicates a subdivision of the lung; when tidal volume is precisely measured, as in gas exchange calculation, the symbol TV or VT is used.)
RVResidual volume: the volume of air remaining in the lungs after a maximal exhalation
ERVExpiratory reserve volume: the maximal volume of air that can be exhaled from the end-expiratory position
IRVInspiratory reserve volume: the maximal volume that can be inhaled from the end-inspiratory level
ICInspiratory capacity: the sum of IRV and TV
IVCInspiratory vital capacity: the maximum volume of air inhaled from the point of maximum expiration
VCVital capacity: the volume of air breathed out after the deepest inhalation.
VTTidal volume: that volume of air moved into or out of the lungs during quiet breathing (VT indicates a subdivision of the lung; when tidal volume is precisely measured, as in gas exchange calculation, the symbol TV or VT is used.)
FRCFunctional residual capacity: the volume in the lungs at the end-expiratory position
RV/TLC%Residual volume expressed as percent of TLC
VAAlveolar gas volume
VLActual volume of the lung including the volume of the conducting airway.
FVCForced vital capacity: the determination of the vital capacity from a maximally forced expiratory effort
FEVtForced expiratory volume (time): a generic term indicating the volume of air exhaled under forced conditions in the first t seconds
FEV1Volume that has been exhaled at the end of the first second of forced expiration
FEFxForced expiratory flow related to some portion of the FVC curve; modifiers refer to amount of FVC already exhaled
FEFmaxThe maximum instantaneous flow achieved during a FVC maneuver
FIFForced inspiratory flow: (Specific measurement of the forced inspiratory curve is denoted by nomenclature analogous to that for the forced expiratory curve. For example, maximum inspiratory flow is denoted FIFmax. Unless otherwise specified, volume qualifiers indicate the volume inspired from RV at the point of measurement.)
PEFPeak expiratory flow: The highest forced expiratory flow measured with a peak flow meter
MVVMaximal voluntary ventilation: volume of air expired in a specified period during repetitive maximal effort

The FEV1/FVC ratio, also called modified Tiffeneau-Pinelli index, [1] is a calculated ratio used in the diagnosis of obstructive and restrictive lung disease. [2] [3] It represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). [4] FEV1/FVC ratio was first proposed by E.A. Haensler in 1950. [5] The FEV1/FVC index should not be confused with the FEV1/VC index (Tiffeneau-Pinelli index) as they are different, although both are intended for diagnosing airway obstruction. Current recommendations for diagnosing pulmonary function recommend using the modified Tiffeneau-Pinelli index (also known as the Haensler index). [6] This index is recommended to be represented as a decimal fraction with two digits after the decimal point (for example, 0.70).

Normal values are approximately 75%. [7] Predicted normal values can be calculated online and depend on age, sex, height, and ethnicity as well as the research study that they are based upon.

A derived value of FEV1% is FEV1% predicted, which is defined as FEV1% of the patient divided by the average FEV1% in the population for any person of similar age, sex, and body composition.

Disease states

In obstructive lung disease, the FEV1 is reduced due to an obstruction of air escaping from the lungs. Thus, the FEV1/FVC ratio will be reduced. [4] More specifically, according to the National Institute for Clinical Excellence, the diagnosis of COPD is made when the FEV1/FVC ratio is less than 0.7 or [8] the FEV1 is less than 75% of predicted; [9] however, other authoritative bodies have different diagnostic cutoff points. [10] The Global Initiative for Chronic Obstructive Lung Disease criteria also require that values are after bronchodilator medication has been given to make the diagnosis. According to the European Respiratory Society (ERS) criteria, it is FEV1% predicted that defines when a patient has COPD—that is, when the patient's FEV1% is less than 88% of the predicted value for men, or less than 89% for women. [10]

In restrictive lung disease, the FEV1 and FVC are equally reduced due to fibrosis or other lung pathology (not obstructive pathology). Thus, the FEV1/FVC ratio should be approximately normal, or even increased due to a decrease in magnitude of FVC as compared to FEV1 (because of the decreased compliance associated with the presence of fibrosis in some pathological conditions). [4]

Related Research Articles

<span class="mw-page-title-main">Lung volumes</span> Volume of air in the lungs

Lung volumes and lung capacities refer to the volume of air in the lungs at different phases of the respiratory cycle.

<span class="mw-page-title-main">Spirometry</span> Pulmonary function test

Spirometry is the most common of the pulmonary function tests (PFTs). It measures lung function, specifically the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Spirometry is helpful in assessing breathing patterns that identify conditions such as asthma, pulmonary fibrosis, cystic fibrosis, and COPD. It is also helpful as part of a system of health surveillance, in which breathing patterns are measured over time.

<span class="mw-page-title-main">Interstitial lung disease</span> Diseases of the space or tissue between the alveoli of the lungs

Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium and space around the alveoli of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.

<span class="mw-page-title-main">Pulmonary fibrosis</span> Disease that causes scarring of the lungs

Pulmonary fibrosis is a condition in which the lungs become scarred over time. Symptoms include shortness of breath, a dry cough, feeling tired, weight loss, and nail clubbing. Complications may include pulmonary hypertension, respiratory failure, pneumothorax, and lung cancer.

<span class="mw-page-title-main">Peak expiratory flow</span> Persons maximum speed of expiration

The peak expiratory flow (PEF), also called peak expiratory flow rate (PEFR) and peak flow measurement, is a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. It measures the airflow through the bronchi and thus the degree of obstruction in the airways. Peak expiratory flow is typically measured in units of liters per minute (L/min).

Airway obstruction is a blockage of respiration in the airway that hinders the free flow of air. It can be broadly classified into being either in the upper airway (UPA) or lower airway (LOA).

<span class="mw-page-title-main">Bronchiolitis obliterans</span> Obstruction of the lungs small airways (bronchioles) due to inflammation

Bronchiolitis obliterans (BO), also known as obliterative bronchiolitis, constrictive bronchiolitis and popcorn lung, is a disease that results in obstruction of the smallest airways of the lungs (bronchioles) due to inflammation. Symptoms include a dry cough, shortness of breath, wheezing and feeling tired. These symptoms generally get worse over weeks to months. It is not related to cryptogenic organizing pneumonia, previously known as bronchiolitis obliterans organizing pneumonia.

<span class="mw-page-title-main">Idiopathic pulmonary fibrosis</span> Scarring of the lungs for no known reason

Idiopathic pulmonary fibrosis (IPF) synonymous with cryptogenic fibrosing alveolitis is a rare, progressive illness of the respiratory system, characterized by the thickening and stiffening of lung tissue, associated with the formation of scar tissue. It is a type of chronic pulmonary fibrosis characterized by a progressive and irreversible decline in lung function.

A bronchial challenge test is a medical test used to assist in the diagnosis of asthma. The patient breathes in nebulized methacholine or histamine. Thus the test may also be called a methacholine challenge test or histamine challenge test respectively. Both drugs provoke bronchoconstriction, or narrowing of the airways. Whereas histamine causes nasal and bronchial mucus secretion and bronchoconstriction via the H1 receptor, methacholine utilizes the M3 receptor for bronchoconstriction. The degree of narrowing can then be quantified by spirometry. People with pre-existing airway hyperreactivity, such as asthmatics, will react to lower doses of drug.

<span class="mw-page-title-main">Obstructive lung disease</span> Category of respiratory disease characterized by airway obstruction

Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung result from narrowing (obstruction) of the smaller bronchi and larger bronchioles, often because of excessive contraction of the smooth muscle itself. It is generally characterized by inflamed and easily collapsible airways, obstruction to airflow, problems exhaling, and frequent medical clinic visits and hospitalizations. Types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Although COPD shares similar characteristics with all other obstructive lung diseases, such as the signs of coughing and wheezing, they are distinct conditions in terms of disease onset, frequency of symptoms, and reversibility of airway obstruction. Cystic fibrosis is also sometimes included in obstructive pulmonary disease.

Restrictive lung diseases are a category of extrapulmonary, pleural, or parenchymal respiratory diseases that restrict lung expansion, resulting in a decreased lung volume, an increased work of breathing, and inadequate ventilation and/or oxygenation. Pulmonary function test demonstrates a decrease in the forced vital capacity.

<span class="mw-page-title-main">Pulmonary function testing</span> Test to evaluate respiratory system

Pulmonary function testing (PFT) is a complete evaluation of the respiratory system including patient history, physical examinations, and tests of pulmonary function. The primary purpose of pulmonary function testing is to identify the severity of pulmonary impairment. Pulmonary function testing has diagnostic and therapeutic roles and helps clinicians answer some general questions about patients with lung disease. PFTs are normally performed by a pulmonary function technologist, respiratory therapist, respiratory physiologist, physiotherapist, pulmonologist, or general practitioner.

Pulmonary rehabilitation, also known as respiratory rehabilitation, is an important part of the management and health maintenance of people with chronic respiratory disease who remain symptomatic or continue to have decreased function despite standard medical treatment. It is a broad therapeutic concept. It is defined by the American Thoracic Society and the European Respiratory Society as an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities. In general, pulmonary rehabilitation refers to a series of services that are administered to patients of respiratory disease and their families, typically to attempt to improve the quality of life for the patient. Pulmonary rehabilitation may be carried out in a variety of settings, depending on the patient's needs, and may or may not include pharmacologic intervention.

<span class="mw-page-title-main">Acute exacerbation of chronic obstructive pulmonary disease</span> Medical condition

An acute exacerbation of chronic obstructive pulmonary disease, or acute exacerbations of chronic bronchitis (AECB), is a sudden worsening of chronic obstructive pulmonary disease (COPD) symptoms including shortness of breath, quantity and color of phlegm that typically lasts for several days.

The BODE index, for Body-mass index, airflow Obstruction, Dyspnea, and Exercise, is a multidimensional scoring system and capacity index used to test patients who have been diagnosed with chronic obstructive pulmonary disease (COPD) and to predict long-term outcomes for them. The index uses the four factors to predict risk of death from the disease.

<span class="mw-page-title-main">Chronic obstructive pulmonary disease</span> Lung disease involving long-term poor airflow

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation. GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms due to abnormalities of the airways and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.

The post bronchodilator test, also commonly referred to as a reversibility test, is a test that utilizes spirometry to assess possible reversibility of bronchoconstriction in diseases such as asthma.

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a diffuse parenchymal lung disease which often presents with symptoms of cough and shortness of breath. The pathological definition published by the World Health Organization is “a generalized proliferation of scattered single cells, small nodules, or linear proliferations of pulmonary neuroendocrine (PNE) cells that may be confined to the bronchial and bronchiolar epithelium.” The true prevalence of this disease is not known. To date, just under 200 cases have been reported in the literature. However, with an increase in recognition of this disease by radiologists and pulmonologists, the number of cases has been increasing. DIPNECH predominantly affects middle-aged women with slowly progressive lung obstruction. DIPNECH is usually discovered in one of two ways: 1) as an unexpected finding following a lung surgery; or 2) by evaluation of a patient in a pulmonary clinic with longstanding, unexplained symptoms.

<span class="mw-page-title-main">Emphysema</span> Air-filled enlargement in the bodys tissues

Emphysema is any air-filled enlargement in the body's tissues. Most commonly emphysema refers to the permanent enlargement of air spaces (alveoli) in the lungs, and is also known as pulmonary emphysema.

Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap (ACO), also known as Asthma-COPD Overlap Syndrome (ACOS), is a chronic inflammatory, obstructive airway disease in which features of both asthma and COPD predominate. Asthma and COPD were once thought of as distinct entities; however, in some, there are clinical features of both asthma and COPD with significant overlap in pathophysiology and symptom profile. It is unclear whether ACO is a separate disease entity or a clinical subtype of asthma and COPD. The pathogenesis of ACO is poorly understood, but it is thought to involve both type 2 inflammation as well as type 1 inflammation. The incidence and prevalence of ACO are not well known. The risk factors for ACO are also incompletely understood, but tobacco smoke is known to be a major risk factor.

References

  1. Minelli R. Appunti dalle lezioni di fisiologia umana. La Goliardica Pavese, Pavia, 1992.
  2. Swanney MP, Ruppel G, Enright PL, et al. (2008). "Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction". Thorax. 63 (12): 1046–51. doi: 10.1136/thx.2008.098483 . PMID   18786983.
  3. Sahebjami H, Gartside PS (1996). "Pulmonary function in obese subjects with a normal FEV1/FVC ratio" (PDF). Chest. 110 (6): 1425–9. doi:10.1378/chest.110.6.1425. PMID   8989055. S2CID   25461249. Archived from the original (PDF) on 2019-02-19.
  4. 1 2 3 Interpreting spirometry Archived 2008-07-25 at the Wayback Machine . gp-training.net
  5. Petty, Thomas L. "The history of COPD" (PDF). nlhep.org.
  6. Mirsadraee M, Salarifar E, Attaran D. Evaluation of Superiority of FEV1/VC Over FEV1/FVC for Classification of Pulmonary Disorders. J Cardiothorac Med. 2015; 3(4):355-359. Archived 2017-11-16 at the Wayback Machine
  7. "Forced Expiration". Johns Hopkins University.
  8. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). NICE.org.uk. June 2010
  9. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). NICE.org.uk. June 2010
  10. 1 2 Nathell, L.; Nathell, M.; Malmberg, P.; Larsson, K. (2007). "COPD diagnosis related to different guidelines and spirometry techniques". Respiratory Research. 8 (1): 89. doi: 10.1186/1465-9921-8-89 . PMC   2217523 . PMID   18053200.